<DOC>
	<DOCNO>NCT00074425</DOCNO>
	<brief_summary>The majority HIV infect people worldwide become infected virus heterosexual contact . BufferGel PRO 2000 Gel vaginal gel design prevent woman become infected HIV sexual intercourse HIV infect partner . This study test safety effectiveness gel .</brief_summary>
	<brief_title>BufferGel PRO 2000/5 : Vaginal Gels Prevent HIV Infection Women</brief_title>
	<detailed_description>Accessible , usable , effective vaginal microbicides could significantly decrease spread HIV . Vaginal microbicides could use condom prevent HIV infection ; could also use situation individual unable negotiate condom use . Vaginal microbicides potentially bidirectional , prevent male-to-female female-to-male HIV transmission . This study evaluate safety effectiveness two vaginal microbicides , BufferGel PRO 2000/5 , prevent transmission HIV . The study also evaluate effectiveness gel prevent common sexually transmitted infection ( STIs ) . BufferGel buffer agent design maintain normal vaginal acidity presence ejaculate . Studies show HIV inactivate pH 4 5.8 . Carbopol 974 , major nonaqueous component BufferGel , commonly use gel tableting agent well-documented safety record . BufferGel proven safe well tolerated Phase I study . PRO 2000/5 inhibits viral entry susceptible cell . PRO 2000/5 also evaluated Phase I study find safe well tolerate . Participants study randomly assign receive one four intervention : BufferGel , PRO 2000/5 , placebo gel , gel . All participant receive HIV risk reduction counseling , condom , diagnosis treatment sexually transmit disease . Participants three gel arm give single-use , prefilled applicator gel instruct apply one dose product ( BufferGel , PRO 2000/5 , placebo gel ) intravaginally 60 minute vaginal intercourse study . Participants enrol approximately 12 30 month , depend enter study . Participants two screen study visit monthly visit . Monthly study visit may take place clinic , participant 's home , community site . Monthly visit include medical interview ; urine testing , include pregnancy testing ; HIV sexually transmit infection risk reduction counseling ; distribution study supply ( condoms gel-filled applicator ) . Blood collection occur select monthly visit . Four time year , participant see clinic structure medical interview , pelvic exam , HIV test . At one visit , participant particular site willing ask complete behavioral risk assessment . At visit vaginal fluid swab occur . Participants non-US study site ask permission swab store test . Assessment interview face face self-reporting .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Note : Per 12/15/06 amendment , study participant enter Phase IIb study . HIV uninfected Have sexual intercourse least 3 month prior study entry Able provide adequate contact information study official purpose followup History adverse reaction latex Nonmedical injection drug use 12 month prior study entry Vaginal intercourse average two time per day 2 week prior study entry Plan become pregnant 30 month study entry Plan travel away study site 3 consecutive month 30 month study entry Plan relocate away study site 30 month study entry Participation another clinical trial vaginal product Pregnant within 42 day study entry Have sexually transmit disease reproductive tract infection diagnose study staff Abnormal pelvic exam indicate deep epithelial disruption Condition , opinion investigator , may interfere study Liver kidney function abnormality Grade 3 high Blood blood clot abnormality Grade 4 high</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Anti-Infective Agents , Local</keyword>
	<keyword>BufferGel</keyword>
	<keyword>PRO 2000</keyword>
	<keyword>Vagina</keyword>
	<keyword>Risk Factors</keyword>
</DOC>